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PVIEWPOINT AND COMMENTARY
Time to Foster a Rational Approach to
Preventing Cardiovascular Morbid Events
Jay N. Cohn, MD, Daniel A. Duprez, MD, PHD
Minneapolis, Minnesota
Efforts to prevent atherosclerotic morbid events have focused primarily on risk factor prevention and interven-
tion. These approaches, based on the statistical association of risk factors with events, have dominated clinical
practice in the last generation. Because the cardiovascular abnormalities eventuating in morbid events are de-
tectable in the arteries and heart before the development of symptomatic disease, recent efforts have focused
on identifying the presence of these abnormalities as a more sensitive and specific guide to the need for ther-
apy. Advances in noninvasive techniques for studying the vasculature and the left ventricle now provide the op-
portunity to use early disease rather than risk factors as the tool for clinical decision making. A disease scoring
system has been developed using 10 tests of vascular and cardiac function and structure. More extensive data
to confirm the sensitivity and specificity of this scoring system and to demonstrate its utility in tracking the re-
sponse to therapy are needed to justify widespread application in clinical practice. (J Am Coll Cardiol 2008;52:
327–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.085r
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mfforts to prevent atherosclerotic disease morbidity during
he past generation have emphasized risk factor prevention
nd treatment. Indeed, the recent commentary in the
ournal by Greenland and Lloyd-Jones (1) advocates greater
ational attention to risk factor prevention to counteract
hat could otherwise be a future increase in cardiovascular
orbid events in the U.S.
The problem with the message to prevent and treat risk
actors is that it may be good public health policy but does
ot translate into a useful strategy for individual patient
are. It is certainly clear that levels of blood pressure (BP)
nd cholesterol are directly associated with the risk of
therosclerotic morbid events, and obesity increases the risk
f diabetes. Furthermore, certain drug treatments that lower
P and lower cholesterol have a favorable effect on the
ncidence of these morbid events. Most data, however,
ndicate that diet has limited long-term effects on low-density
ipoprotein cholesterol or BP (2). Indeed, the observational link
etween BP or cholesterol levels and morbid events identifies
azard ratios that may be impressive from a population
erspective but misleading for a physician dealing with an
ndividual patient (3). Does a 20% or 30% higher risk in one
atient justify an intervention that is not to be used in the
atient without such increased risk? That seems to be a
rom the Rasmussen Center for Cardiovascular Disease Prevention, University of
innesota Medical School, Minneapolis, Minnesota. Dr. Cohn is a director of and
olds equity in Cohn Prevention Centers, LLC.v
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008, accepted February 27, 2008.emarkably crude and imprecise approach to decision making.
isk factors are not the disease.
The investigators cite the Third National Health and
utrition Examination Survey (NHANES-3) data that
ore than 99% of men between the ages of 35 and 74 years
ave at least one risk factor (4). If true, what value are risk
actors in defining risk? At best they would have a sensitivity
n the 90% range but a specificity near 0. So what is the
hysician charged with doing to advise or treat his or her
atients? If one waits to treat until BP or cholesterol reach
he threshold for guideline-mandated interventions, then
any morbid events will occur before treatment is instituted
nd many patients not destined to suffer morbid events may
e treated unnecessarily. The TROPHY (Trial of Prevent-
ng Hypertension) trial suggests that development of arterial
ypertension could be prevented if drug treatment were
tarted earlier (5).
Relying on ubiquitous risk factors in defining treatment
trategies to prevent morbid events has been abandoned in
he cancer field. Recent evidence of a steep decline in cancer
eaths in the U.S. has been attributed largely to identifying
arly disease in asymptomatic individuals by routine screen-
ng with techniques such as mammography, colonoscopy,
ap smears, and prostate antibody screening (6). No such
creening for early cardiovascular disease (CVD) has been
dvocated or reimbursed by insurance companies in the U.S.
The traditional approach to preventing CVD has been
he modest primary prevention risk reduction strategies
roposed by Greenland and Lloyd-Jones (1) or the phar-
acologic secondary prevention widely recognized to pre-
ent recurrent events in patients who have already suffered
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Where is a strategy akin to the
success in cancer prevention:
early recognition and aggressive
intervention?
Atherosclerotic disease ante-
dates morbid events by years. It
can now be recognized by easily
erformed noninvasive testing. We have developed a
lobal model for assessing vascular and cardiac health and
dentifying early disease. It consists of 7 vascular and 3
ardiac functional and structural tests performed in 1 h by
ne technician in a single room (8). The 7 vascular tests
nclude large and small artery elasticity (compliance),
itting BP, BP response during a moderate treadmill
xercise test, optic fundus photography, measurement of
arotid intimal-media thickness and microalbuminuria.
he 3 cardiac tests include an electrocardiogram, left
entricular (LV) ultrasonography for LV volume and
ass, and determination of blood N-terminal pro-B-type
atriuretic peptide level. These individual cardiovascular
ests were selected on the basis that they are predictive of
ardiovascular morbidity and mortality (9). Table 1
ummarizes the disease score, identified as the Rasmus-
en score, named for the benefactor of our center, and the
coring of each test. Each of the 10 tests is scored as
ollows: 0 for normal, 1 for borderline abnormal, and 2
or abnormal. The total score for any individual test may
herefore range from 0 to 20. We have now screened
,500 patients. One-third of this population has a Ras-
ussen disease score between 0 and 2 (low disease risk),
ne-third between 3 and 5, and one-third 6 and above,
hich is considered high risk. Our preliminary data
ndicate that this disease score is far superior to risk factor
ssessment and Framingham 10-year risk scores in iden-
ifying those destined for morbid events. Why has the
rofession not embraced this approach in identifying
ndividuals in need of pharmacopreventive therapy? In-
eed, all of the recent prospective trial data show the
ramatic benefit on outcome of drugs to lower cholesterol
Abbreviations
and Acronyms
BP  blood pressure
CVD  cardiovascular
disease
LV  left ventricular
asmussen Disease Score With the Scoring of Each Individual Vas
Table 1 Rasmussen Disease Score With the Scoring of Each In
Test Normal
Score for each test 0
Large artery elasticity
Small artery elasticity
Resting BP (mm Hg) SBP 130 and DBP 85
Treadmill exercise BP (mm Hg) SBP increase 30 and SBP 169
Optic fundus photography retinal vasculature A/V ratio 3:5
Carotid IMT
Microalbuminuria (mg/mmol) 0.6
Electrocardiogram No abnormalities
LV ultrasound LVMI (g/m2) 120
NT-proBNP (pg/dl) 150/V arteriole-to-venule; BP blood pressure; DBP diastolic blood pressure; IMT intimal-media thick
atriuretic peptide; RDS  Rasmussen disease score; SBP  systolic blood pressure.nd BP but less documentation of benefits from risk
actor reduction through lifestyle changes alone.
The time has come to enter a new era in which we focus
n early disease rather than risk factors. We now know how
o identify and track the arterial and cardiac disease that will
ventually make people sick. Recently we showed in the
ETECTIV (Detection and Treatment of Early Cardio-
ascular Disease Trial: Intervention with Valsartan) study
hat the angiotensin II receptor blocker valsartan could
educe the Rasmussen disease score in asymptomatic high-
isk patients with pre-hypertension or BP controlled to
140/90 mm Hg (10). We should seize the opportunity to
dentify asymptomatic individuals with the disease and treat
t. That is something physicians can and should do. It would
ikely be more effective and understandable than the vague
ublic health approaches we have advocated for the last
eneration. Clinical trials to document the cost effectiveness
f this approach are urgently needed.
eprint requests and correspondence: Dr. Jay N. Cohn, Cardio-
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